[The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?]
Denosumab is an effective treatment for osteoporosis. However, an increasing number of patients are developing so-called rebound vertebral fractures, because of a considerable increase of bone resorption after cessation of denosumab therapy. The prevalence of these new vertebral fractures is still unknown. In patients with high risk of new fractures, it is recommended to consider continuing denosumab treatment, or to switch to another antiresorptive medication such as bisphosphonates.